Repurposing of Drugs as Novel Influenza Inhibitors from Clinical Gene Expression Infection Signatures
August 2018
in “
bioRxiv (Cold Spring Harbor Laboratory)
”
Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.
Studysummary This study identifies diltiazem as a promising repurposed drug for treating influenza, supported by its antiviral activity and gene modulation effects, leading to a Phase II clinical trial authorization.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer